Molecular Devices partners with SEED Biosciences to exclusively offer DispenCell Single-Cell Dispenser, expanding leadership in cell line development

DispenCell Single-Cell Dispenser

Technology enables scientists to isolate single cell lines three times faster and at lower cost compared to existing solutions

SAN JOSE, Calif., Feb. 7, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, has entered into a partnership with SEED Biosciences Ltd, a solutions company for single-cell assays. Molecular Devices is now an exclusive commercial supplier of the award-winning DispenCell™ Single-Cell Dispenser – an automated laboratory instrument designed for fast, easy, and gentle single-cell isolation – in the United States and Asia, with reseller rights in most of Europe.

“Integrating the DispenCell Single-Cell Dispenser into our portfolio of automated, end-to-end solutions for cell line development workflows will further strengthen our ability to help the scientific community industrialize biology,” said Susan Murphy, President of Molecular Devices. “With an accessible price point and ease of use, the DispenCell Single-Cell Dispenser pairs particularly well with our CloneSelect® Imager FL to enhance, streamline, and assure monoclonality verification right from the start.”

Accurate single-cell isolation with immediate, traceable proof of monoclonality is critical to a successful cell line development process. However, isolating a monoclonal cell population by the manual and time-consuming limiting dilution method – which can include three rounds of cloning – leads to high variability in results. Alternatively, the automated DispenCell Single-Cell Dispenser requires just one round of cloning and a single plate, offering significant efficiency improvements.

The DispenCell Single-Cell Dispenser offers:

“Selecting Molecular Devices as an exclusive provider was an easy decision to make, as we share a purpose to help scientists develop safer, more efficient biotherapies faster, and at lower costs,” said Georges Muller, SEED Biosciences’ CEO and co-founder. “Expanding our reach through Molecular Devices and with the strength of our combined technologies, we will enable more clients to overcome bottlenecks and maximize their single-cell cloning, CRISPR gene-editing, and single-cell omics assays as well as their cell line development workflows.”

For more information, visit

About Molecular Devices, LLC.

Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe. Visit Molecular Devices at

About SEED Biosciences Ltd

By accelerating the use of precision medicine in personalised therapies, SEED Biosciences aims to set new standards in single-cell biology to benefit patients. To do this, we provide scientists with innovative tools that are gentle with cells, affordable, intuitive and – most importantly – compliant with the most stringent regulatory demands. Our first product, DispenCellTM, enables scientists to isolate single cell lines three times faster and ten times cheaper than existing solutions. The award-winning company is headquartered in Switzerland. Visit SEED Biosciences at visit